Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database

Rheumatology (United Kingdom)

Volumn 53, Issue 10, 2014, Pages 1864-1871

  Moulis, Guillaume ^a,b,c,d   Sommet, Agnès ^a,b,c   Lapeyre Mestre, Maryse ^a,b,c   Montastruc, Jean Louis ^a,b,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UMR INSERM 1027   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Disproportionality analysis; Drug induced lupus; TNF a antagonists

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; CORTICOSTEROID; DNA ANTIBODY; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; ISONIAZID; METHOTREXATE;

ADULT; AGED; ARTHRITIS; ARTICLE; CASE STUDY; COMPARATIVE STUDY; CROHN DISEASE; DISEASE CLASSIFICATION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LUPUS LIKE SYNDROME; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; REFERENCE DATABASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; YOUNG ADULT;

EID: 84924845009     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu214     Document Type: Article

References (20)

1. Ramos-Casals M, Roberto Perez-Alvarez Diaz-Lagares C et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9: 188–93.
2. Grönhagen CM, Fored CM, Linder M et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol 2012;167: 296–305.
3. Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008;58:1248–57.
4. Chang C, Gershwin ME. Drugs and autoimmunity—a contemporary review and mechanistic approach. J Autoimmun 2010;34:J266–75.
5. Cortes-Hernandez J, Egri N, Vilardell-Tarres M et al. Safety and efficacy of etanercept in systemic LUPUS erythematosus [abstract]. Arthritis Rheum 2012;64:S616.
6. Wetter DA, Davis MDP. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009;84:979–84.
7. Santiago T, Santiago MG, Rovisco J et al. A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-a agent? Clin Rheumatol 2013;32:1819–22.
8. Akgül O, Kılıç G, Kılıç E et al. A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept. Rheumatol Int 2014;34:443–4.
9. Ye C, Sholter D, Martin L et al. Successful switch of patients with rheumatoid arthritis developing anti-tumor necrosis factor (anti-TNF)-induced lupus to another anti-TNF agent. J Rheumatol 2011;38:1216.
10. Montastruc J-L, Sommet A, Lacroix I et al. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine 2006; 73:629–32.
11. Montastruc J-L, Sommet A, Bagheri H et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 2011;72:905–8.
12. Salvo F, Leborgne F, Thiessard F et al. a potential eventcompetition bias in safety signal detection: results from a spontaneous reporting research database in France. Drug Saf 2013;36:565–72.
13. Pariente A, Avillach P, Salvo F et al. Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf 2012;35:855–64.
14. Ramos-Casals M, Brito-Zerón P, Soto MJ et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22:847–61.
15. Mattozzi C, Salvi M, D'Epiro S et al. Importance of regulatory T cells in the pathogenesis of psoriasis: review of the literature. Dermatology (Basel) 2013;227: 134–45.
16. Cullen G, Kroshinsky D, Cheifetz AS et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011;34:1318–27.
17. Fautrel B, Joubert J-M, Cukierman G et al. Rheumatoid arthritis (RA), comorbidities and biological agents uptake in France: analysis of a national claims database. Ann Rheum Dis 2013;72:337.
18. Schabert VF, Watson C, Gandra SR et al. Annual costs of tumour necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ 2012;15:264–75.
19. Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev 2012;11:321–5.
20. Verma HD, Scherl EJ, Jacob VE et al. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab. J Dig Dis 2011;12: 379–83.